GlobeNewswire

2024-12-12 15:00

Essential Pharma announces €900 million recapitalisation through a Gyrus Capital Continuation Vehicle led by AlpInvest and new strategic financing from Sixth Street

Essential Pharma announces €900 million recapitalisation through a Gyrus Capital Continuation Vehicle led by AlpInvest and new strategic financing from Sixth Street

Provides significant resources to build on diversified portfolio of established and rare disease medicines

Egham, UK – 12 December 2024 – Essential Pharma (“Essential” or “the Company”), an international specialty pharma group focused on ensuring that patients have access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, today announces the completion of a €900 million financing, through a Gyrus Capital single-asset Continuation Vehicle led by AlpInvest, a subsidiary of Carlyle Global Investment Solutions, and a new strategic financing facility with Sixth Street.  

Essential Pharma was acquired in 2019 by Gyrus Capital, who have supported the transformation of the Company into a global, high-growth specialty pharma group with significant development opportunities. The transaction will enable Essential to deploy additional capital to build on its diversified portfolio and late-stage pipeline across established and rare disease medicines. This will be achieved through its successful acquisition and development strategy under the leadership of CEO, Emma Johnson. This additional capital will support Essential’s mission to ensure access to essential medicines for patients across new and existing markets. Since her appointment in 2023, Emma has driven the Company’s expansion into rare diseases, with the addition of marketed product Colobreathe® and Hu14.18, an immunotherapy in late-stage clinical development for the treatment of high-risk neuroblastoma.

Following the transaction, Lee Morley, appointed as Non-Executive Director to the Board in 2023, will assume the role of Chairman of Essential Pharma, succeeding Dr Patrick Vink. Lee has more than 30 years’ experience in the biopharmaceutical industry, with extensive knowledge of commercialisation, pricing, reimbursement and product launch strategy. He was a co-founder and CEO at EUSA Pharma before the company’s €750 million acquisition by Recordati (BIT: REC) in 2022. During his time at EUSA Pharma, he led the company’s transition from specialty pharma to oncology and rare disease, driving sales from €20 million to €150 million.

Emma Johnson, CEO of Essential Pharma, commented: “This transaction provides us with substantial additional firepower, strengthening our ability to deliver essential medicines to patients who need them most. By moving into new geographical markets and building on our diversified portfolio and late-stage pipeline across our key therapeutic areas, we can expand our reach to help underserved patient populations across the globe. We are excited to continue our relationship with Gyrus Capital as we execute our strategy to become a leading, global specialty pharma group with a growing rare disease presence, where patient needs are often most acute. As we transition to our new ownership, I’d also like to thank Patrick for his significant contributions as Chairman and welcome Lee as he steps into the role.”

Dr Robert Watson, Managing Partner at Gyrus Capital, said: “This is a landmark investment for Essential and for Gyrus Capital. We are delighted to partner with AlpInvest, Stepstone, Sixth Street and other significant private capital institutions, who believe in our shared vision of building an exceptional specialty pharma company, and bringing critical medical products to patients across the globe.”

Sixth Street, a leading global investment firm with deep experience supporting biotech companies across all stages of growth, is providing a new strategic financing facility consisting of €300 million in structured equity and growth debt.

Jeff Pootoolal, Partner at Sixth Street who will join the board of Essential Pharma, said: “Essential Pharma has assembled a leading team and platform in its pursuit of providing patients around the world with critical medicines. We are excited to support Emma and Essential’s leadership as they continue to execute and expand on their mission.”

About Essential Pharma

Essential Pharma is an international specialty pharmaceutical group dedicated to maintaining access to clinically differentiated, niche, branded medicines across multiple therapeutic areas. The group has been an important and valued partner to healthcare providers for over 20 years by giving underserved patient populations access to medicines that otherwise might not be available, and addressing clinical unmet needs. Essential Pharma operates globally in more than 70 countries, supplying a portfolio of products with a focus on the central nervous system (CNS), gastroenterology, ophthalmology, and rare disease. The group’s growth strategy is centred on portfolio optimisation and a targeted M&A approach to acquire commercial and late-clinical stage assets in the four therapeutic areas of focus. It is a trusted partner to multiple pharma companies of all sizes, with a proven history of integrating assets and managing complex technology transfers seamlessly while ensuring continuous supply to patients.

For more information, please visit essentialpharmagroup.com

About Gyrus Capital

Gyrus Capital is a European investment firm dedicated to transformational investments in the healthcare and sustainability sectors. Based in Geneva, Switzerland, Gyrus invests in businesses that address the structural needs of society and the environment and are positioned for long-term sustainable growth. The firm focuses on complex transactions, particularly corporate carve-outs in the €50 million to €500 million range. A renowned group of experienced partners and industry experts supports Gyrus’s active investment and value-creation approach, working closely with entrepreneurs and managers. To learn more, please visit www.gyruscapital.com

About Sixth Street

Sixth Street is a global investment firm with over $80 billion in assets under management and committed capital. Sixth Street uses its long-term flexible capital, data-enabled capabilities, and One Team culture to develop themes and offer solutions to companies across all stages of growth. Sixth Street Healthcare and Life Sciences finances the development and commercialization of innovative therapeutics and invests in healthcare technology companies across all stages of growth. Investments in the sector include Apellis Pharmaceuticals, Arrowhead Pharmaceuticals, Arsenal Biosciences, Biohaven, Blueprint Medicines, Caris Life Sciences, Chroma Medicine, ConcertAI, Datavant, Immunogen, Ironwood, and Mammoth Biosciences, among many others. Founded in 2009, Sixth Street has more than 650 team members including over 250 investment professionals operating around the world. For more information, visit www.sixthstreet.com, or follow Sixth Street on LinkedIn.

CONTACTS

Essential Pharma

Emma Johnson, CEO

Tel: +44(0)1784 477 167

Email: info@essentialpharmaceuticals.com

ICR Healthcare

Tracy Cheung/Sukaina Virji/Isabelle Abdou

Tel: +44 (0) 20 3709 5700

Email: Essentialpharma@icrhealthcare.com


Primary Logo

source: Essential Pharma

【你點睇?】渣馬4名內地跑手被取消資格,4人同屬一個經理人,號碼布疑被調換,你認為主辦方應否酌情處理?► 立即投票

人氣文章
最近7天
1
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
2
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
3
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
4
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
5
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
6
港股 | 蕭猷華:恒指短線回調,中線繼續看好
7
AI | DeepSeek日活躍用戶達二千萬,據報在港設兩公司
8
神州經脈 | 多國限制用DeepSeek,美郵政恢復收中港包裹
9
iPhone SE 4或於本周內上架官網
10
關稅戰 | 觸發避險金價屢創新高看3000美元,應揀買金礦股抑或黃金ETF?
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
3
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
4
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
5
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
6
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
7
一本萬利 | 2025年的五個「勿」(有片)
8
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
9
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
10
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
11
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
12
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
13
【FOCUS】去年貿易順差破紀錄,中國擴消費增緊迫感
14
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
15
【FOCUS】侵侵就職倒數一周,美元及油價劇本臨揭盅
16
習近平應約與特朗普通電話,特:冀盡快與習見面
17
洪灝專訪 | 淘寶衝擊巨大,港樓價未反映大周期拐點(有片)
18
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
19
雷賢達觀點 | 香港篇:恒指年波幅料六千點,港須全面融入大灣區
20
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
21
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
22
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
23
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
24
加州山火造成超500億美元損失,大量房主未買保險
25
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
26
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
27
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
28
特朗普就職 | 特朗普上台後行動列表
29
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
30
馬斯克明拆特朗普台,指其星際之門計劃「假大空」
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

流感高峰期

山今養生智慧

輕鬆護老